{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Aod-9604",
    "short_name": "AOD-9604",
    "aliases": [
      "hGH fragment 176-191"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Not FDA-approved for human therapeutic use; widely sold as research-grade peptide."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-17",
      "human_use_note": "AOD-9604 is not approved for human therapeutic use. Despite this, it is widely marketed and consumed as a research peptide, particularly in weight-loss contexts. No regulatory body currently authorizes it for medical treatment."
    },
    "structure": {
      "sequence_oneletter": "",
      "amino_acid_seq": "YLRIVQCRSVEGSCGF",
      "molecular_formula": "",
      "molecular_weight": null,
      "structure_image_url": ""
    },
    "risk": {
      "current_score": 4,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "human_interventional",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Short-term human studies suggest limited adverse effects, but long-term safety data are sparse. The peptide mimics a fragment of human growth hormone, raising theoretical concerns around endocrine signaling, metabolic adaptation, and developmental exposure in adolescents.",
      "developmental_systems_of_concern": [
        "gh_igf",
        "metabolic",
        "puberty"
      ]
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "moderate",
          "evidence_grade": "human_interventional",
          "text": "AOD-9604 is a synthetic peptide derived from amino acids 176–191 of human growth hormone. It was developed to isolate the lipolytic (fat-metabolizing) effects of hGH without stimulating growth or insulin-like growth factor pathways.",
          "evidence_refs": [
            "E1",
            "E2"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "subcutaneous",
          "unit": "mcg",
          "min": 250,
          "max": 500,
          "frequency": "daily",
          "duration": "up to 12 weeks",
          "population_group": "general",
          "notes": "Descriptive only. Observed in clinical studies; not instructions.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "mechanistic_only",
          "text": "Use during adolescence may interfere with normal endocrine signaling and metabolic regulation. Long-term developmental effects have not been studied and may be irreversible.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": []
    },
    "interactions": {
      "drug_classes": [],
      "supplement_classes": [],
      "peptides": []
    },
    "evidence": [
      {
        "id": "E1",
        "title": "A double-blind, placebo-controlled study of AOD-9604 for obesity",
        "source_type": "pubmed",
        "source_id": "15615612",
        "url": "https://pubmed.ncbi.nlm.nih.gov/15615612/",
        "published_date": "2005-01-01",
        "evidence_grade": "human_interventional",
        "notes": "Human trial evaluating weight-loss effects and safety over 12 weeks.",
        "year": 2004
      },
      {
        "id": "E2",
        "title": "Lipolytic domain of human growth hormone",
        "source_type": "pubmed",
        "source_id": "12183452",
        "url": "https://pubmed.ncbi.nlm.nih.gov/12183452/",
        "published_date": "2002-01-01",
        "evidence_grade": "mechanistic_only",
        "notes": "Identified the 176–191 fragment responsible for fat metabolism signaling.",
        "year": 2002
      }
    ],
    "changelog": [
      {
        "date": "2026-01-17",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for AOD-9604",
        "detail": "Created first alphabetical peptide entry with human and mechanistic evidence.",
        "evidence_refs": [
          "E1",
          "E2"
        ]
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_fat_loss_metabolism"
      ]
    },
    "slug": "aod-9604"
  },
  "canonical_name": "Aod-9604"
}
